New adjuvant chemocherapy for resectable pancreatic cancer base on ctDNA Multi-omics biomarker: a prospective, multi-center study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035577

Enrollment

Unknown

Registered

2020-08-14

Start date

2020-10-30

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

1:surgery+chemotherapy

2:adjuvant chemo+ surgery+ chemo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. assign the informed consent; 2. aged 18 to 75 years; 3. resectable pancreatic cancer; high-risk pancreatic cancer patients should have pathology before chemotherapy; 4. no other adjuvant therapy or other anticancer therapy; 5. sufficient renal and marrow function; 6. sufficent hepatic function; 7. no fever, on evidence of infection.

Exclusion criteria

Exclusion criteria: 1. malfunction of heart orlung; 2. Hb<70g/L or albumin<30g/L preoperation; 3. history of organ transplantation; 4. taking of steroid, immunsuppressive drugs or chemotherapy; 5. HIV; 6. suspicious of imcompliance or incoordination; 7. autoimmune disease; 8. mental disease or other defects; 9. unresectable pancreatic cancer or acute pancreatitis during operation; 10. could not follow up post-operation; 11. positive or HCG; 12. coexistence of other tumors.

Design outcomes

Primary

Measure	Time frame
overall survival;no progress of disease;	—

Countries

China

Contacts

Public ContactLou Wenhui

Zhongshan Hospital, Fudan University

lou.wenhui@zs-hospital.sh.cn+86 18616881868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026